

Product Data Sheet

Product Name: (S)-JDQ-443
Cat. No.: GC69904

Chemical Properties

Cas. No. 2653994-10-4

Formula C₂₉H₂₈ClN₇O M.Wt 526.03

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure (S)-JDQ-443

Background

(S)-JDQ-443 is an isomer of 2). JDQ-443 is an orally active, potent, selective, and covalent **KRAS G12C** inhibitor (extracted from patent WO2021120890A1). JDQ-443 shows antitumor activity^{[1][2]}.

JDQ-443 inhibits ERK/pERK phosphorylation in KRASG12C NCI-H358 and NCI-H2122 cells with IC₅₀ values of 0.018 and 0.063 μM^[2].

JDQ443 inhibits GDP release from KRASG12C and RAS II in the presence of KRASG12C and KRAS G12C/H95/G12C/R68S and G12C/Y96 mutants^[2].

JDQ443 (10-100 mg/kg) significantly inhibits tumor growth in KRAS G12C CDX models^[2].

JDQ443 (100 mg/kg) + 7.5 mg/kg TNO155 (36 weeks) significantly inhibits tumor growth in CDX models^[2].

JDQ443 inhibits NSCLC growth in PDX models^[2].

[1]. LIU BO, et al. PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS. Patent WO2021120890A1.

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

[2]. Weiss A, Lorthiois E, Barys L, et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent and Selective, Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022;candisc.0158.2022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA